BusinessZafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association’s 77th Annual Scientific SessionsBy Nasdaq OMXJun 10, 2017, 5:00 PM UTC
